ArticleFrontiers in pediatrics2026
Predicting neurodevelopmental outcomes in neonatal hyperbilirubinemia: a multidimensional nomogram integrating biomarkers and neurobehavioral scores.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The long-term neurodevelopmental trajectories of neonates with hyperbilirubinemia lacking overt acute symptoms remain largely unknown. This study aimed to evaluate these trajectories and develop a predictive model integrating multidimensional biomarkers with early neurobehavioral screenings to forecast neurodevelopmental impairment at one year of age. Methods: In this prospective observational study of 234 term neonates, clinical characteristics were recorded at admission, and laboratory results were obtained within the first 24 h. Early Neonatal Behavioral Neurological Assessment (NBNA) was performed, and neurodevelopment was assessed at 12 months of age using the Gesell Developmental Schedules. Key predictors were selected by integrating LASSO regression results with prior knowledge and clinical significance. A multivariable logistic regression model was subsequently constructed to develop a prognostic nomogram, internally validated using bootstrap resampling. Results: At the 12-month follow-up, 12.8% (30/234) of the infants exhibited neurodevelopmental impairment. Multivariable analysis identified elevated C-reactive protein (CRP, OR = 1.097, 95% CI: 1.026, 1.172), a higher bilirubin-to-albumin ratio (B/A, OR = 2.587, 95% CI: 1.497, 4.471), and increased neuron-specific enolase (NSE, OR = 1.285, 95% CI: 1.092, 1.513) as independent risk factors for adverse outcomes. Higher NBNA scores (OR = 0.749, 95% CI: 0.608, 0.922) served as an independent protective factor. The model yielded an apparent area under the curve (AUC) of 0.813 and an optimism-corrected AUC of 0.797 (95% CI: 0.696-0.902), demonstrating stable discriminative power. Calibration plots showed consistency between predicted and observed probabilities, with a Brier score of 0.09. Decision curve analysis indicated clinical net benefit across a range of threshold probabilities. Conclusion: Neonates with hyperbilirubinemia may experience subclinical neurodevelopmental impairment. Our model facilitates risk stratification, supporting targeted long-term follow-up and developmental monitoring for high-risk infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.